William S. Kearney

Jan 10, 2024 | gis.stackexchange.com | William S. Kearney

I receive the following error log when I try.

Nov 2, 2023 | issues.org | Tom Burroughs |Jennifer Doudna |William S. Kearney

Big First for Gene Editing November 2, 2023 The FDA appears ready to approve the first commercial use of gene editing to treat a disease. In this case, a drug company is seeking to use the gene-editing tool CRISPR to treat sickle cell disease, an inherited blood disorder. “It’s extraordinary to think that we’re on the verge of an approval of the first CRISPR therapy,” Jennifer Doudna, a CRISPR codiscoverer, tells NPR.

Jul 26, 2023 | issues.org | Tom Burroughs |Jennifer Doudna |William S. Kearney

A new company is pushing to reformulate the gene-editing tool CRISPR in hope of tackling a range of hard-to-treat diseases, and investors are eyeing a potential multibillion-dollar market, Forbes magazine reports. In an Issues interview, Jennifer Doudna, who shared a Nobel Prize for her role in developing the foundational technology—and is also a cofounder of the company—cautions that commercialization must proceed carefully, with input from scientists, policymakers, and the public alike.

Jul 10, 2023 | issues.org | Vol. XXXIX |Ben Bernanke |William S. Kearney

What happens when innovation slips the bounds and intent of its makers? Many experts worry that the result could be destabilization and mayhem. This is perfectly reasonable for intelligence and defense innovation that deals in powerful, potentially dangerous technologies. And in the context of the COVID-19 pandemic, during which people died because of bad information about vaccines and misuse of inappropriate drugs, a security lens on health seems warranted.